Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDO2 | P48775 | 12/20 | 1.00 |
| ▸ | IDO1 | P14902 | 11/20 | 1.00 |
| ▸ | NOS1 | P29475 | 3/20 | 0.46 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.46 |
| ▸ | METAP2 | P50579 | 2/20 | 0.46 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.44 |
| ▸ | JAK2 | O60674 | 1/20 | 0.44 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.44 |
| ▸ | AXL | P30530 | 1/20 | 0.41 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1118862 | 1.00 | TDO2 (1.00) | TDO2IDO1NOS1DYRK1AMETAP2 | |
| SCHEMBL17875686 | 0.79 | TDO2 (0.66) | TDO2IDO1NOS1DYRK1AMETAP2 | |
| SCHEMBL1709837 | 0.76 | IDO1 (0.61) | TDO2IDO1NOS1DYRK1AMETAP2 | |
| SCHEMBL1318814 | 0.76 | TDO2 (0.61) | TDO2IDO1NOS1DYRK1AMETAP2 | |
| SCHEMBL30861084 | 0.76 | IDO1 (0.61) | TDO2IDO1METAP2CHEK1 | |
| SCHEMBL16618130 | 0.76 | IDO1 (0.61) | TDO2IDO1NOS1DYRK1AMETAP2 | |
| SCHEMBL2289231 | 0.76 | IDO1 (0.61) | TDO2IDO1NOS1DYRK1AMETAP2 | |
| SCHEMBL304051 | 0.76 | IDO1 (0.61) | TDO2IDO1METAP2CHEK1 | |
| SCHEMBL22499161 | 0.76 | TDO2 (0.61) | TDO2IDO1NOS1DYRK1AMETAP2 | |
| SCHEMBL29410369 | 0.76 | IDO1 (0.61) | TDO2IDO1NOS1DYRK1AMETAP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024073073-A2 | KINASE MODULATORS AND METHODS OF USE THEREOF | NEURON23, INC. (US) | 2024-04-04 | — | — | WO | disclosed |
| US-11446306-B2 | Bicyclic bromodomain inhibitors | ZENITH EPIGENETICS LTD. (CA) | 2022-09-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11446306-B2 | Bicyclic bromodomain inhibitors | BRD4, BRD3, BRD2 | TDO2 4012/4885IDO1 1654/4885NOS1 4773/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.